Abstract
Multiple sclerosis, an organ-specific autoimmune disease of the central nervous system, affects 250,000 to 350,000 persons in the United States. It is at least twice as common among women as among men — a sex distribution common to most autoimmune diseases. The clinical manifestations of multiple sclerosis reflect its multifocal involvement, and its course may be subacute, with relapses followed by remissions, or chronic and progressive.1 The diagnosis can be established with different degrees of confidence as probable or definite on the basis of clinical features alone or clinical features in combination with oligoclonal abnormalities of immunoglobulins in cerebrospinal fluid, . . .